Premium
Poor responses to tyrosine kinase inhibitors in a child with precursor B ‐cell acute lymphoblastic leukemia with SNX 2‐ ABL 1 chimeric transcript
Author(s) -
Masuzawa Aki,
Kiyotani Chikako,
Osumi Tomoo,
Shioda Yoko,
Iijima Kazutoshi,
Tomita Osamu,
Nakabayashi Kazuhiko,
Oboki Keisuke,
Yasuda Kazuki,
Sakamoto Hiromi,
Ichikawa Hitoshi,
Hata Kenichiro,
Yoshida Teruhiko,
Matsumoto Kenji,
Kiyokawa Nobutaka,
Mori Tetsuya
Publication year - 2014
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12234
Subject(s) - fusion gene , dasatinib , imatinib , abl , chromosomal translocation , tyrosine kinase , cancer research , fusion protein , tyrosine kinase inhibitor , lymphoblastic leukemia , leukemia , fusion transcript , medicine , imatinib mesylate , oncogene proteins , gene , biology , immunology , genetics , myeloid leukemia , regulation of gene expression , signal transduction , cancer , recombinant dna
In addition to BCR , various rare fusion partners for the ABL 1 gene have been reported in leukemia. We have identified the fusion gene SNX 2‐ ABL 1 in a pediatric case of acute lymphoblastic leukemia ( ALL ), which has only once previously been reported in an adult patient. Cytogenetic analysis detected this fusion gene arising from a t(5;9)(q22;q34) translocation. ALL cells carrying a SNX 2‐ ABL 1 fusion exhibited a BCR ‐ ABL 1 + ALL ‐like gene expression profile. The patient poorly responded to dasatinib but partially responded to imatinib. Treatment using tyrosine kinase inhibitors requires further investigation to optimize the genotype‐based treatment stratification for patients with SNX 2‐ ABL 1 fusion.